Efficacy and limitations of senolysis in atherosclerosis. Issue 7 (17th June 2021)

• Record Type: Journal Article
• Authors: Garrido, Abel Martin; Kaistha, Anuradha; Uryga, Anna K; Oc, Sebnem; Foote, Kirsty; Shah, Aarti; Finigan, Alison; Figg, Nichola; Dobnikar, Lina; Jørgensen, Helle; Bennett, Martin
• Is Part Of: Cardiovascular research. Volume 118:Issue 7(2022)
• Page Start: 1713
• Page End: 1727
• Publication Date: 2021-06-17
• Subjects: Atherosclerosis -- Ageing -- Cell senescence; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Periodicals; 616.1
• DOI: 10.1093/cvr/cvab208
• Languages: English
• ISSNs: 0008-6363

Abstract

Abstract: Aims: Traditional markers of cell senescence including p16, Lamin B1, and senescence-associated beta galactosidase (SAβG) suggest very high frequencies of senescent cells in atherosclerosis, while their removal via 'senolysis' has been reported to reduce atherogenesis. However, selective killing of a variety of different cell types can exacerbate atherosclerosis. We therefore examined the specificity of senescence markers in vascular smooth muscle cells (VSMCs) and the effects of genetic or pharmacological senolysis in atherosclerosis. Methods and results: We examined traditional senescence markers in human and mouse VSMCs in vitro, and in mouse atherosclerosis. p16 and SAβG increased and Lamin B1 decreased in replicative senescence and stress-induced premature senescence (SIPS) of cultured human VSMCs. In contrast, mouse VSMCs undergoing SIPS showed only modest p16 up-regulation, and proliferating mouse monocyte/macrophages also expressed p16 and SAβG. Single cell RNA-sequencing (scRNA-seq) of lineage-traced mice showed increased p16 expression in VSMC-derived cells in plaques vs. normal arteries, but p16 localized to Stem cell antigen-1 (Sca1) + or macrophage-like populations. Activation of a p16-driven suicide gene to remove p16 + vessel wall- and/or bone marrow-derived cells increased apoptotic cells, but also induced inflammation and did not change plaque size or composition. In contrast, the senolytic ABT-263 selectively reduced senescent VSMCs in culture, and markedly reduced atherogenesis. However, ABT-263 did not reduce senescence markers in vivo, and significantly reduced monocyte and platelet counts and interleukin 6 as a marker of systemic inflammation. Conclusions: We show that genetic and pharmacological senolysis have variable effects on atherosclerosis, and may promote inflammation and non-specific effects respectively. In addition, traditional markers of cell senescence such as p16 have significant limitations to identify and remove senescent cells in atherosclerosis, suggesting that senescence studies in atherosclerosis and new senolytic drugs require more specific and lineage-restricted markers before ascribing their effects entirely to senolysis. Graphical Abstract: